US 12,115,197 B2
Microbial compositions for the treatment of skin diseases
Jared Kehe, Cambridge, MA (US); Bernardo Cervantes, Cambridge, MA (US); Cheri Ackerman, Somerville, MA (US); Abdulrahman Hassaballah, Boston, MA (US); and Keaton Armentrout, Seattle, WA (US)
Assigned to Concerto Biosciences, Inc., Cambridge, MA (US)
Filed by Concerto Biosciences, Inc., Cambridge, MA (US)
Filed on Feb. 28, 2024, as Appl. No. 18/589,539.
Application 18/589,539 is a continuation of application No. PCT/US2022/079637, filed on Nov. 10, 2022.
Claims priority of provisional application 63/278,134, filed on Nov. 11, 2021.
Prior Publication US 2024/0189369 A1, Jun. 13, 2024
Int. Cl. A61K 35/741 (2015.01); A61K 31/51 (2006.01); A61P 31/04 (2006.01); C12N 1/20 (2006.01); C12R 1/07 (2006.01)
CPC A61K 35/741 (2013.01) [A61K 31/51 (2013.01); A61P 31/04 (2018.01); C12N 1/20 (2013.01); C12R 2001/07 (2021.05)] 27 Claims
 
1. A composition, wherein the composition comprises:
bacterial strains that are purified, lyophilized, and comprise:
a first bacterial strain, which is a Lysinibacillus strain that comprises a 16S rRNA gene sequence with at least 98% sequence identity to SEQ ID NO: 2; and
a second bacterial strain, which is a Bacillus strain that comprises a 16S rRNA gene sequence with at least 99% sequence identity to SEQ ID NO: 4, and wherein the composition comprises an effective amount of a lyoprotectant.